


Supplementary Figure 1



**Supplementary Table 1. Baseline demographics and disease characteristics**

	<b>Panitumumab + FOLFOX4</b>	<b>FOLFOX4</b>
	<b>(n = 253)</b>	<b>(n = 252)</b>
Sex		
Male	170 (67)	158 (63)
Female	83 (33)	94 (37)
Age (years), median (range)	61 (27–81)	61 (24–82)
ECOG performance score, n (%)		
0 or 1	238 (94)	235 (93)
2	15 (6)	17 (7)
Primary tumour diagnosis, n (%)		
Colon	165 (65)	164 (65)
Rectum	88 (35)	88 (35)
Prior adjuvant chemotherapy, n (%)		
Yes	42 (17)	38 (15)
No	211 (83)	214 (85)
Median EuroQoL score (range)		
Health State Index	0.796 (–0.484, 1.00)	0.796 (–0.005, 1.00)
Overall Health Rating	77.0 (0.0, 100)	70.0 (6.0, 100)

Abbreviations: ECOG = Eastern Cooperative Oncology Group; EQ-5D, EuroQoL 5-domain.

**Supplementary Table 2. Skin toxicity adverse events (any grade) occurring in  $\geq 5\%$  of patients in either treatment arm**

<b>Adverse event, n (%)</b>	<b>Panitumumab + FOLFOX4 (n = 253)</b>	<b>FOLFOX4 (n = 252)</b>
Rash	139 (56)	20 (8)
Dermatitis acneiform	85 (34)	0 (0)
Pruritus	64 (26)	11 (4)
Dry skin	56 (22)	13 (5)
Erythema	42 (17)	9 (4)
Skin fissures	42 (17)	1 (<1)
Acne	37 (15)	1 (<1)
Palmar-plantar erythrodysesthesia syndrome	27 (11)	7 (3)